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Abstract
Background: Up to three quarters of surgical patients receive inadequate pain relief, with 40% of patients reporting
severe pain following knee replacement, which may indicate the current pain relief strategies using opiate-based
analgesia cannot achieve patient satisfaction. Liposomal bupivacaine is liposome-encapsulated bupivacaine which
has been reported to be effective for up to 72 h. The study of Peri-Articular Anaesthetic for Replacement of the
Knee (SPAARK) trial has been designed to assess the effectiveness of peri-articular liposomal bupivacaine and
bupivacaine hydrochloride compared with peri-articular bupivacaine hydrochloride alone in the management of
post-operative pain following knee replacement.
Methods/design: The SPAARK trial is a multi-centre, patient-blinded, randomised controlled trial. The co-primary
outcomes are post-operative recovery assessed by global QoR-40 scores at 72 h and cumulative pain VAS score
from 6 to 72 h following surgery. Longer-term measures of the co-primary outcomes are collected at 6 weeks and 6
and 12 months post randomisation, together with secondary outcomes, i.e. the Oxford Knee Score, and the
American Knee Society Score. Cumulative opiate use and fitness for discharge are measured up to 72 h post-
surgery. The analysis approaches for the primary and secondary outcomes are described here, as are the descriptive
statistics which will be reported. The full SPAARK protocol has already been published.
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Results: The co-primary outcomes will be analysed using multivariate linear regression adjusting for stratification
factors and other important prognostic variables, including baseline scores in the case of the QoR-40. The adjusted
mean difference between the two groups together with 97.5% confidence intervals will be reported for each of the
primary outcomes. Other continuous variables will be assessed using the same method. Binary outcomes will be
assessed using chi-squared tests.
Discussion: The paper provides details of the planned statistical analyses for the SPAARK trial and aims to reduce
the risk of outcome reporting bias from prior data knowledge. Any changes or deviations from this statistical
analysis plan will be described and justified in the final study report.
Trial registration: ISRCTN54191675. Registered on 13 November 2017.
Keywords: Statistical analysis plan, Randomised controlled trial, Knee replacement, Liposomal bupivacaine,
Bupivacaine hydrochloride
Background
Around 100,000 primary knee replacements are per-
formed in the UK each year [1]. It has been reported
that up to three quarters of surgical patients receive in-
adequate pain relief, with 40% of patients reporting se-
vere pain following knee replacement [2–5]. Optimising
peri-operative pain management through the use of
multi-modal analgesia reduces the surgical stress re-
sponse and permits early rehabilitation whilst optimising
recovery benefits for both the patients (reduced morbid-
ity and mortality) and the healthcare system (reduced
costs) [6]. Current pain relief strategies use opiate-based
analgesia; however, these drugs have significant side ef-
fects seen in up to 50% of patients. Opioid-sparing tech-
niques have been associated with enhanced patient
satisfaction in the acute phase and there is increasing
evidence about their longer-term benefits [7].
The concept of multi-modal analgesia was introduced
two decades ago [8]. Multiple studies report the superior-
ity of multi-modal analgesia over single agent therapy [8–
10]. Local anaesthetic infiltration is commonly used as
part of a multi-modal technique; however, the length of
duration of action is a major limiting factor of current
local anaesthetic techniques. Liposomal bupivacaine is
liposome-encapsulated bupivacaine which has been re-
ported to be effective for up to 72 h [11, 12]. Liposomal
bupivacaine is not yet licensed in the UK for any indica-
tion, whereas, in the USA, it was licensed by the FDA in
October 2011 with evidence of patients discharged on the
day of surgery following knee and hip replacement with
no reported incidents of increased readmission rates or
wound issues [13–15]. A series of randomised controlled
trials have investigated the use of liposomal bupivacaine
for post-operative pain; however, a recent Cochrane Re-
view has demonstrated no sufficient evidence to support
the use of liposomal bupivacaine in the management of
post-operative pain following knee replacement [16].
The Study of Peri-Articular Anaesthetic for Replace-
ment of the Knee (SPAARK) trial is a multi-centre,
patient-blinded, randomised controlled trial designed
to assess the effectiveness of peri-articular liposomal
bupivacaine with bupivacaine hydrochloride compared
to bupivacaine hydrochloride alone on post-operative
recovery (systemic and local) in patients undergoing
knee replacement surgery. The protocol paper for the
SPAARK trial has been published previously [17]; the
aim of this paper is to report in detail the analysis
plan as agreed by the trial steering committee in
January 2020. This paper has been prepared according
to the published guidelines on the content of statis-
tical analysis plans [18].
Methods and design
Trial design
The SPAARK trial is a patient-blinded, multi-centre,
active comparator, two-arm, parallel group, rando-
mised, controlled, superiority trial (RCT) comparing
the effectiveness of peri-articular liposomal bupivacaine
and bupivacaine hydrochloride with bupivacaine hydro-
chloride alone for post-operative recovery after knee re-
placement surgery. Patients are randomised in a 1:1
ratio using stratified randomisation with variable block
sizes stratified by study centre and operation type (total
knee replacement (TKR) or unicompartmental knee re-
placement (UKR)). Patients are blinded as to which
treatment they receive. Surgeons are not blinded to
treatment allocation. The trial has been powered for
two primary endpoints, Quality of Recovery (QoR-40)
at 72 h post-surgery and cumulative pain score from 6
to 72 h post-surgery. Secondary outcomes are assessed
at baseline, days 0, 1, 2, and 3, 6 weeks, and 6 and 12
months after randomisation. Full details of the trial de-
sign, study population, and study procedures have been
published previously [17].
The trial is registered with the International Standard
Randomised Controlled Trials database, ISRCTN refer-
ence number ISRCTN54191675.
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Objectives
The primary objective of this trial is to evaluate the clinical
effectiveness of liposomal bupivacaine and bupivacaine
hydrochloride compared with bupivacaine hydrochloride
alone on post-operative recovery. The secondary objec-
tives include assessing other markers of recovery both in
the short term and the long term.
Outcomes
Primary outcome
The primary objective of improved patient recovery is
assessed at two primary endpoints: global QoR-40 scores
at 72 h post-surgery and cumulative pain score from 6 to
72 h following surgery. The QoR-40 has been widely
used across a range of surgeries including knee replace-
ment to assess the overall post-operative recovery [19].
It is a validated patient reported peri-operative recovery
score that incorporates five dimensions of health: patient
support, comfort, emotions, physical independence, and
pain. Each QoR-40 item is graded on a five-point Likert
scale with the total score range from 40 (extremely poor
quality of recovery) to 200 (excellent quality of recovery)
[20]. Missing QoR-40 items will be imputed using me-
dian imputation based on the other questions in the
same domain if 3 or fewer answers are missing. If more
than 3 answers are missing, no imputation of the miss-
ing answers and the total score will be treated as
missing.
The cumulative pain score is measured using a visual
analogue scale (VAS) ranging from 0 (no pain) to 10
(worst possible pain). Measurements are taken at base-
line, 6, 24, 48, and 72 h post-surgery. Cumulative score
is calculated as area under the curve (AUC) from 6 to
72 h post-surgery.
Secondary outcomes
Longer-term measures of the co-primary outcomes, glo-
bal QoR-40 scores, and the pain VAS score are collected
at 6 weeks and 6 and 12 months post-randomisation.
The other secondary outcome measures are as follows:
 Cumulative opiate use—all opioids used on evening
of surgery (day 0) and days 1, 2, and 3 are recorded
and a running total of cumulative opioid use
calculated. A list of acceptable opioids is provided in
the trial protocol [17].
 Fitness for discharge is assessed against pre-defined
criteria on evening of surgery (day 0) and days 1, 2,
and 3 following surgery as per routine clinical care.
Patients are considered fit for discharge when they
meet four criteria: (i) ability to mobilise independ-
ently; (ii) pain score less than or equal to 3 cm on a
10 cm VAS scale; (iii) ability to straight leg raise; and
(iv) ability to bend knee to 90°.
 Oxford Knee Score (OKS)—a 12-item patient-
reported outcome measure designed to measure
pain and function after knee replacement surgery
[21]. Each question is scored from 0 (worst out-
come) to 4 (best outcome), and a total score be-
tween 0 (worst score) and 48 (best score) is obtained
by summing across all 12 items. This outcome will
be assessed at 6 weeks and 6 and 12 months post-
randomisation.
 American Knee Society Score (AKSS)—a subjective,
patient-reported outcome measure that evaluates pa-
tient satisfaction, patient expectations, and ability to
perform functional activities [22]. The patient satis-
faction score composes 5 questions with a maximum
score of 40. The patient expectation score composes
3 questions with a maximum score of 15. The func-
tional score is composed of 4 subgroups (walking
and standing; standard activities; advanced activities
and discretionary activities) with a maximum score
of 100. Higher scores indicate better performance.
This outcome will be assessed at 6 weeks and 6 and
12 months post-randomisation.
Sample size
The trial has been powered for two primary endpoints,
QoR-40 at 72 h post-surgery and cumulative pain score
from 6 to 72 h post-surgery, with adjustment for multi-
plicity using the Bonferroni method [23]. The trial will
be assessed as providing evidence of a difference if either
of the two primary endpoints is statistically and clinically
significant.
The study requires 240 patients per treatment arm in
order to be 90% powered to detect a 5 point difference
in global QoR-40 score between groups at a significance
level of 0.025 (2-sided, adjusted for multiplicity) assum-
ing the standard deviation is 15.5 [24]. To allow for 4%
loss to follow-up, this has been inflated to 500 patients
(250 per treatment arm). Low loss to follow-up is antici-
pated for this study since the co-primary outcomes are
up to 72 h post-operation.
The study also requires a minimum of 225 patients per
treatment arm in order to be 90% powered to detect a
standardised difference of 33% between groups in cumula-
tive pain score calculated as area under the curve from 6
to 72 h post-surgery at a significance level of 0.025 (2-
sided, adjusted for multiplicity). Inflating the sample size
to 500 patients (250 per treatment arm) allows for 10%
loss to follow-up on this variable; therefore, we propose to
recruit 500 patients in total (250 per treatment arm).
Statistical analysis
General analysis principles
Two analysis populations will be considered, the intent-
to-treat (ITT) population and the per-protocol (PP)
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population. The ITT population will include participants
in the group they were randomised to, regardless of
treatment actually received. The PP population is a sub-
set of the ITT population, which excludes participants
with major protocol deviations. Major protocol devia-
tions include participants who (i) did not receive the
treatment to which they were randomised, (ii) did not
provide sufficient follow-up data for analysis, or (iii) did
not satisfy the eligibility criteria for the study. The defin-
ition of the PP population will be reviewed and finalised
during a blinded analysis of the data prior to the primary
analysis time-point.
A significance level of 0.025 will be used and 97.5%
confidence intervals will be presented for each of the
two primary outcomes. The trial will be considered to
have a positive result if either of the dual primary out-
comes returns a positive result at the 0.025 significance
level. All secondary analyses will be considered as sup-
porting the primary analysis and will be analysed using a
significance level of 0.05 with 95% confidence intervals.
The primary conclusion of the trial will be based on the
results from the primary analysis of the co-primary out-
comes. For the co-primary outcomes, a sensitivity ana-
lysis will be carried out on a per-protocol basis using the
definition of the PP population. Sensitivity analyses for
checking the validity of multiple imputation assump-
tions, if applicable, will be performed.
A cost utility analysis (CUA) will also be performed
using quality-adjusted life years (QALYs) as the main
health outcome, obtained using the EuroQol EQ-5D-5L
questionnaire at baseline, on the evening of surgery (day
0) and days 1, 2, and 3, 6 weeks, 6 months, and 1 year.
The CUA will be undertaken by the trial health econo-
mist and is not included in the statistical analysis plan.
A separate Health Economic Analysis Plan (HEAP) will
be available on request once the CUA is published.
No formal comparative interim analyses of the co-
primary outcomes nor any formal subgroup analyses are
planned during the trial.
All analysis will be carried out using appropriate vali-
dated statistical software such as STATA [25] or R [26].
The relevant package and version number will be
recorded.
Descriptive analyses
The flow of participants through the trial will be sum-
marised as outlined in Fig. 1. This will include the num-
ber of individuals screened, eligible, randomised to each
group, receiving their allocated treatment, and included
in the primary analysis as suggested in the CONSORT
guidelines [27]. Reasons for ineligibility, loss to follow-
up, and exclusion from the primary analysis will be sum-
marised, as will the number of patients who withdraw
before each analysis time point.
The baseline comparability of the two randomised
groups in terms of (i) stratification factors, (ii) baseline
characteristics (Table 1), and (iii) surgery details (Table 2).
Numbers with percentages will be used to compare binary
and categorical variables, and either means and standard
deviations or medians and interquartile ranges will be
used for continuous variables. There will be no tests of
statistical significance nor confidence intervals for differ-
ences between the randomised groups.
Loss to follow-up, withdrawals, and missing data
The numbers (and percentages) of losses to follow-up
and withdrawals along with reasons for these will be re-
ported by intervention arm at each time point. Any
deaths and their causes will be reported separately.
For each of the co-primary and secondary outcomes,
the number and percentages of individuals in the miss-
ing category will be presented by treatment group, along
with reasons for missingness if known. The pattern of
missingness will also be explored. Based on the available
data, the possibility of informative missingness, or data
being missing not at random cannot be ruled out.
Therefore, sensitivity analysis will examine the effect of
missing data on the trial conclusions assuming that data
are missing not at random, that is that those with miss-
ing data may have different outcomes than those with
observed follow-up data.
Compliance
The trial and control drugs are administered as a single
intra-operative dose via peri-articular infiltration.
Amount of drug administered will be recorded. As such
patient compliance is not relevant to these drugs. If, for
any reason, the randomised intervention is not delivered,
this will be recorded along with the reason for not re-
ceiving the randomised treatment. The instances will be
summarised by treatment group and differences between
the two treatment groups will be explored. In addition,
surgeon compliance with the administration of the IMP
will also be summarised.
Analysis of the co-primary outcomes
Primary analysis
QoR-40 scores at 72 h post-surgery will be summarised
by treatment group using unadjusted means and associ-
ated standard deviations. QoR-40 scores from baseline
to 12 months post-randomisation will also be sum-
marised by treatment group using a boxplot. A mixed ef-
fects linear regression model adjusting for type of
surgery, baseline QoR-40 scores, age, and gender as fixed
effects and recruitment centre as a random effect will be
used to compare QoR-40 scores at 72 h post-surgery.
The adjusted mean difference between the arms, associ-
ated 97.5% confidence interval, and associated p value
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will be reported. The assumption of approximate nor-
mality of the residuals will be assessed graphically.
Pain scores from baseline to 12 months post-
randomisation will be summarised by treatment group
using a boxplot. A summary statistics approach will be
used to calculate the AUC of cumulative daily pain
scores from 6 to 72 h post-surgery [28]. Specifically, pa-
rameters from a repeated measures mixed effects linear
regression model will be used to calculate the pain AUC
for each treatment group. The model will include re-
peated measures of the pain scores (from 6 to 72 h post-
surgery) (level 1) nested within participants (level 2) and
adjusted for recruitment centre as a random effect (level
3). Time will be treated as categorical and a treatment
by time interaction will be included. The model will be
adjusted for type of surgery, baseline pain score, age,
gender, and the use of pre-operative opiate pain medica-
tion as fixed effects. The AUC for each treatment group
and associated standard deviation will be calculated.
Time will be treated linearly and AUCs will be calcu-
lated for the median values of continuous covariates and
most common value of categorical covariates. The AUC
for each treatment group and associated SD will be cal-
culated following the formula lay out by Bell et al. [28]
and using the lincom command in Stata. Similar
Table 1 Baseline characteristics
Baseline characteristic Type Levels or scale
Sex Binary Male; female
Age Continuous Years
BMI Continuous kg/m2
Knee Binary Left; right
Type of surgery Binary TKR; UKR
Fig. 1 CONSORT flow diagram for participants in the SPAARK trial
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methods will be used to calculate the difference between
the two groups which will be compared using a t test;
mean differences with 97.5% confidence intervals will be
provided. The assumption of approximate normality of
the residuals of the mixed effects model will be assessed
graphically.
If, in either case, approximate normality of the resid-
uals is not appropriate, the first approach will be to con-
sider a transformation of the data. If approximate
normality of the residuals cannot be achieved by trans-
formation, the data will be analysed using a non-
parametric equivalent with no adjustment. In the case of
the AUC analysis, this may result in a return to the sum-
mary measures approach as described in detail in the
next section.
The primary analysis for each of the co-primary out-
comes is an available case analysis. The potential effect
of informatively missing data on the QoR-40 will also be
assessed as a sensitivity analysis. Hereby outcomes for all
of those with missing outcome data, and separately for
those with missing outcome data in the treatment group,
will be assumed to be, on average, up to 5 points worse
than under a missing at random assumption. Five points
on the QoR-40 were chosen as this was the target differ-
ence used in the sample size calculation.
Missing pain scores at 6, 24, 48, and 72 h for those in
the whole sample known to have been discharged from
hospital at the relevant time point will be replaced by a
pain score of 3, i.e. the cutoff for participants being
deemed fit for discharge; for those in the whole sample
not known to have been discharged from hospital by the
relevant time point will be imputed with the worst pain
score observed across both trial groups at this time
point.
Secondary analysis
Repeated measures of each of the primary outcomes (at
6, 24, 48, 72 h, 6 weeks, 6 months, and 12 months) will
be modelled using multi-level mixed-effects linear re-
gression models. The assumption of approximate nor-
mality of the residuals will be assessed graphically. These
models will use repeated measures (level 1) nested
within participants (level 2) and will include a random
effect to account for heterogeneity in response due to re-
cruitment centre (level 3). The models will also include
fixed effects for type of surgery (TKR versus UKR), base-
line values, age, gender, and, in the case of the pain
scores, use of pre-operative opiate pain medication.
Time will be treated as categorical and interactions be-
tween treatment and time will be included in the model
to allow for treatment effects to vary over the follow-up.
The adjusted difference between treatment groups (and
associated 97.5% confidence interval) will be reported.
If, in either case, approximate normality of the resid-
uals is not appropriate, the first approach will be to con-
sider a transformation of the data. If approximate
normality cannot be achieved by transformation, the
data will be analysed separately at each time point using
a non-parametric equivalent with no adjustment. Me-
dians and inter-quartile ranges will be reported for each
treatment group.
In addition, a summary measures approach to cumula-
tive pain will also be used as a supporting analysis for this
outcome. For each participant, cumulative pain score from
6 to 72 h post-surgery will be calculated as the area under
the curve based on linear interpolation between available
time points. Participants with missing pain scores at either
6 or 72 h will be excluded from this analysis. Pain score
AUCs will be summarised by treatment group using un-
adjusted means and associated standard deviations. A
multivariate linear regression will be used to compare the
AUCs between the treatment groups, adjusted as de-
scribed previously. The adjusted difference (97.5% CI) and
associated p value will be presented.
Analysis of secondary outcomes
Continuous outcomes (OKS and each AKSS domain)
will be summarised over time (from baseline to 12
months post- randomisation) by treatment groups using
boxplots and will be analysed using similar methods to
those outlined for the secondary analysis of the primary
outcomes. Multi-level, mixed-effects linear regression
models analogous to those described previously will be
used.
Table 2 Surgery details by treatment group
Surgery details Type Levels or scale
Time from randomisation to surgery Integer Days
Theatre time Integer Minutes
Type of surgery received Binary TKR or UKR; and whether this differs from what was planned at randomisation
Number of staff present Integer Reported separately for anaesthetists, surgeons and nursing staff
ASA grade Categorical Grade I, grade II and grade III
Anaesthetic used Categorical General, neuraxial—spinal, neuraxial—epidural, block—femoral, block—sciatic, block—adductor
canal, and block—lumbar plexus
Intra-operative complications Integer Total number of complications and number of patients with at least one complication
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Mean imputation based on the response to all other
questions will be used for missing items on the OKS if 2
or fewer answers are missing. If more than 2 answers are
missing, the total score will be treated as missing.
For AKSS, mean imputation will be applied to missing
items in the patient satisfaction and expectations do-
mains. If fewer than 50% of answers are missing, mean
imputation based on the response to all other questions
in the same domain will be used. If 50% or more of the
answers are missing, the total score will be treated as
missing. The functional score domain composes of four
subgroups, including walking and standing, standard ac-
tivities, advanced activities, and discretionary activities.
No imputation will be undertaken for the walking and
standing domain. Mean imputation will be used for
standard and advanced activities domains. In the discre-
tionary activities domain where participants are asked to
select up to 3 activities and rate how much bother their
knee gives them during this activity, if a patient indicates
less than three activities, two assumptions will be inves-
tigated: (i) assume that where a discretionary activity is
missing, this does not necessarily mean they could not
do any; therefore, mean imputation will be used. If no
activities are given, the discretionary activities score will
be treated as missing. (ii) Assume that where a discre-
tionary activity is missing, this is because the participant
could not do any further discretionary activities, and a
score of zero will be given for this activity (worst score).
If no activities are given, the discretionary activities score
will be treated as zero.
Cumulative opiate use will be approximately continu-
ous; however, it is unlikely to be normally distributed.
As described above, the possibility of transformation to
achieve approximate normality will be considered. If
normality can be achieved, linear regression will be used
as previously described. If this cannot be achieved, a
non-parametric analysis with no adjustment will be
used.
Fitness for discharge is a binary variable. The number
and percentage of patients fit for discharge at days 0, 1,
2, and 3 following surgery will be summarised by treat-
ment group. Any instances where someone is fit for dis-
charge at one time point and not at some subsequent
one will be summarised. The two treatment groups will
be compared using a multi-level logistic regression
model with repeated measures (level 1) nested within
participants (level 2) and adjusted for recruiting centre
as a random effect (level 3). The model will also be ad-
justed for type of knee replacement, age, and gender as
fixed effects. Time will be included as a categorical co-
variate and a treatment-by-time interaction will be in-
cluded. Adjusted ORs and associated 95% confidence
intervals will be reported at each time point. Unadjusted
ORs will also be calculated.
Fitness for discharge and actual discharge status will
also be compared in each treatment group at each time
point. Reasons for discrepancies between these two
values will also be summarised. The average lengths of
time from surgery to being determined fit for discharge
and from being determined fit for discharge to being dis-
charged will be summarised by treatment group using
medians and IQRs.
The total number of complications experienced will be
summarised by treatment group, as well as the number
of participants experiencing at least one complication.
The number of participants experiencing a complication
will be compared using a logistic regression model ad-
justed as outlined previously. Descriptive data on the
types of complications experienced, Clavien-Dindo clas-
sification of complications, and timing of complications
will also be presented.
Analysis of safety data
A serious adverse event (SAE) is any untoward medical
occurrence that results in death, is life-threatening, re-
quires inpatient hospitalisation or prolongation of exist-
ing hospitalisation, results in persistent or significant
disability/incapacity, consists of a congenital anomaly or
birth defect, or is otherwise considered medically signifi-
cant by the investigator.
Any adverse event (AE) occurring within 30 days of
surgery will be recorded if there is a reasonable possibil-
ity it is related to either (i) the administration of the in-
vestigational medical product (IMP) or the control drug
or (ii) the knee replacement surgery. Expectedness and
causality of AEs and SAEs will also be determined. AEs
occurring more than 30 days following surgery will only
be recorded if (i) the event is deemed to be serious
(meets SAE criteria) and there is a reasonable possibility
it is related to the knee replacement surgery or (ii) there
is a patient death.
Details of expected events related to either the adminis-
tration of the IMP during surgery or the knee replacement
surgery itself are provided in the trial protocol [17]. The
number of AEs occurring up to 30 days post-surgery will
be reported by treatment group. The number of partici-
pants experiencing an AE will also be reported by treat-
ment group, and the two groups will be compared. The
number of SAEs, SARs, and SUSARs occurring up to 12
months post-randomisation will be reported by treatment
group. The numbers of participants experiencing an SAE,
SAR, or SUSAR will also be summarised by treatment
group and will be compared between the liposomal bupi-
vacaine + bupivacaine hydrochloride and bupivacaine
hydrochloride alone groups by examination of the 95%
confidence intervals for the difference in incidence. The
analysis will be conducted for the ITT population. The
number of deaths per arm will also be compared.
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Descriptive data on the type of AE reported, as well as
MedDRA codes for the SAEs will also be presented.
Discussion
The SPAARK trial will provide data regarding the clinical
and cost effectiveness of peri-articular liposomal bupiva-
caine compared with bupivacaine hydrochloride alone for
post-operative recovery after knee replacement surgery.
This paper provides details of the planned statistical ana-
lyses for this trial and will help reduce the risks of out-
come reporting bias and data driven results [29].
Trial status
Recruitment for the trial closed on 29 Feb 2020. In total,
533 patients from 11 study sites were recruited. Follow-up
is currently ongoing and expected to finish in February
2021; the analysis of outcomes will be conducted there-
after. The COVID-19 pandemic has no effect on the re-
cruitment of the trial and very limited effect on the
outcomes of the trial in terms of limited activities during
the lockdown period.
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